Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Textiles Press Releases.
Press releases published on June 2, 2025

Asante Receives Second US$100 Million Advance From Fujairah, Provides Interim Financing Update
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Asante Gold Corporation (CSE: ASE | GSE: ASG | FRANKFURT:1A9 | U.S.OTC: ASGOF) (“Asante” or the “Company”) is pleased to announce that it has received the second US$100 million advance from …

Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director Slate
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder …

Coda Octopus Group Sets Fiscal Second Quarter 2025 Earnings Conference Call for Monday, June 16, 2025, at 10 a.m. Eastern Time
Orlando, FL, June 02, 2025 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (NASDAQ: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and new generation augmented …

Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
Trial demonstrated that approximately 35% of semaglutide-induced weight loss was due to loss of lean mass Combining semaglutide with muscle-preserving antibodies protected lean mass – sparing approximately 50%-80% of the lean mass lost with semaglutide …

NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and hand muscle in individuals with a cervical level spinal cord …

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …

SAIC Announces First Quarter of Fiscal Year 2026 Results
Revenues of $1.88 billion; approximately 2% revenue growth Net bookings of $2.4 billion; book-to-bill ratio of 1.3 Net income of $68 million; Adjusted EBITDA(1) of $157 million or 8.4% of revenues Diluted earnings per share of $1.42; Adjusted diluted …

Cancer mRNA Vaccine Clinical Trials FDA Approval mRNA Therapies Clinical Advances Insight
Delhi, June 02, 2025 (GLOBE NEWSWIRE) -- mRNA cancer vaccines approach clinical maturity, the commercial landscape surrounding them is rapidly changing. Over 60 candidates in the works, with a few in Phase III clinical trials, the industry is increasingly …

Pharvaris Presents Data Supporting Ongoing Clinical Development of Deucrictibant in Bradykinin-Mediated Angioedema
Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio …

BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und Kommerzialisierung des bispezifischen Antikörperkandidaten BNT327 in einer Vielzahl solider Tumorarten bekannt
BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard zu setzen, der über die traditionellen …

BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
BNT327, BioNTech’s PD-L1xVEGF-A bispecific antibody, is a clinically advanced investigational immunotherapy candidate with the potential to surpass current checkpoint inhibitor outcomes and set a new standard of care in multiple tumor types The co- …

Brazil Potash Year to Date Summary: Company Achieves Milestones, Advancing Strategic Autazes Project Further Towards Construction
Achievements Include Commercial Agreements, World-Class Board Appointments, Construction Progress, and Enhanced Capital Access Management to Attend Wells Fargo Industrials Conference on June 10, 2025, in Chicago MANAUS, Brazil, June 02, 2025 (GLOBE …

Castellum, Inc. to Participate in the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow” Virtual Conference Presented by Maxim Group LLC on Tuesday, June 3rd – Thursday, June 5th at 9:00 a.m. EDT
VIENNA, Va., June 02, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) announces that its Chief Executive Officer, Glen Ives, has been invited to present at the “2025 Virtual Tech Conference: Discover the Innovations Reshaping Tomorrow,” …

Resumo do Ano da Brazil Potash: Empresa Alcança Marcos Importantes, Avançando o Projeto Estratégico Autazes em Direção à Construção
Conquistas Incluem Acordos Comerciais, Nomeações de Classe Mundial para o Conselho, Progresso na Construção e Acesso Aprimorado ao Capital Administração Participará da Conferência Industrial Wells Fargo em 10 de Junho de 2025, em Chicago MANAUS, Brasil, …

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commercial …

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001) Other prespecified …

First Atlantic Nickel to Attend Benchmark Mineral Intelligence's GIGA USA 2025 Conference, Highlighting Atlantic Nickel Project’s Smelter-Free Processing for North America’s Critical Minerals Supply Chain
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- First Atlantic Nickel Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P21) (“First Atlantic” or the “Company”) is pleased to announce its participation at the Benchmark Mineral Intelligence GIGA USA …

Stomp Into Some Prehistoric Learning! Lingokids and BBC Earth Launch New Walking With Dinosaurs Lesson to Bring a Love of Dinosaurs to a New Generation
LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- Get ready to dig, discover, and roar with excitement. Lingokids and BBC Earth are launching an exclusive Walking with Dinosaurs Lesson in the Lingokids app just in time for Dinosaur Day and the premiere of the …

L’hébergement souverain : un impératif stratégique
Le contexte géopolitique actuel est plus que jamais un signal fort sur la nécessité de repenser nos infrastructures IT et de positionner la souveraineté comme un enjeu central. En effet, au cœur de la création de valeur des entreprises, le numérique est un …

GFG Announces Encouraging Phase 1 Drill Results from Pen Gold Project, Ontario
KEY HIGHLIGHTS: Chabot Target: 3.90 grams of gold per tonne (“g/t Au”) over 3.5 metres (“m”), including 9.62 g/t Au over 1 m near surface (PEN-25-100); second zone returned 2.6 g/t Au over 1.3 m with over 1% zinc (1). Alpha Target (Muskego North Shear Zone …